Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?

E. R. Koomen, A. Joosse, R. M. Herings, M. K. Casparie, W. Bergman, T. Nijsten, H. J. Guchelaar

Research output: Contribution to journalArticleAcademicpeer-review


BACKGROUND: Statins show anticancer activity in melanoma cells. We investigated the association between statins and incidence and Breslow thickness of cutaneous melanoma (CM). METHODS: Data were used from PHARMO, a pharmacy database, and PALGA, a pathological database, in the Netherlands. Cases had a primary CM diagnosis between January 1st 1991 and December 14th 2004, were 18 years and had 3 years of follow up in PHARMO before CM diagnosis. Controls were matched for gender, date of birth and geographic region. Analyses were adjusted for age, gender, year of diagnosis, number of medical diagnoses and the use of NSAIDs and oestrogens. FINDINGS: Finally, 1318 cases and 6786 controls were selected. CM risk was not associated with statin use (> or = 0.5 years) (adjusted odds ratio (OR)=0.98, 95% confidence interval (CI)=0.78-1.2). However, statin use was associated with a reduced Breslow thickness (-19%, 95% CI=-33, -2.3, p=0.03). CONCLUSION: Our study suggests protective effects of statins on melanoma progression.
Original languageEnglish
Pages (from-to)2580-2589
Number of pages10
JournalEuropean Journal of Cancer
Issue number17
Publication statusPublished - 2007


  • Antineoplastic Agents/*therapeutic use Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use Male Melanoma/*drug therapy/pathology/secondary Middle Aged Multivariate Analysis Neoplasm Metastasis/prevention & control Pilot Projects Regression Analysis Skin Neoplasms/*drug therapy/pathology

Cite this